Summit Therapeutics is trading at $16.83, with a -4.05% change, as U.S. markets sell off after hotter-than-expected producer inflation and elevated oil prices.
- The S&P 500 and Nasdaq are each down approximately 0.66%, creating a broad risk-off backdrop.
- No fresh negative company-specific announcement was identified.
- On September 9, Jefferies upgraded Summit Therapeutics to Buy with a $25 target; the bullish call preceded the current decline.